The purpose of this trial is to evaluate the safety and tolerability of long-term administration of Lacosamide at doses up to 400 mg/day in Japanese and Chinese adults with Epilepsy who have completed the Treatment and Transition Period of EP0008 \[NCT01710657\]
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With at Least One Adverse Event Reported Spontaneously by the Subject or Observed by the Investigator From Baseline Until the End of Study Visit
Timeframe: From Visit 1 (Week 0) up to approximately Week 323
Number of Participants That Withdrew Due to Adverse Events From Baseline Until the End of Study Visit
Timeframe: From Visit 1 (Week 0) up to approximately Week 323